BioCryst Pharmaceuticals, Inc. (BCRX) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Biotechnology
EV/EBITDA
6.59
+8% vs avg
5yr avg: 6.11
30Y Low6.1·High6.1
P/FCF
5.71
+10% vs avg
5yr avg: 5.21
30Y Low0.1·High5.2
P/B Ratio
N/A
—
5yr avg: N/A
30Y Low0.4·High15.9
ROE
N/A
—
5yr avg: N/A
30Y Low-285%·High-8%
Debt/EBITDA
1.39
+0% vs avg
5yr avg: 1.39
30Y Low1.4·High1.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BCRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
BioCryst Pharmaceuticals, Inc. trades at 7.4x earnings, 14% above its 5-year average of 6.4x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a discount of 67%. On a free-cash-flow basis, the stock trades at 5.7x P/FCF, 10% above the 5-year average of 5.2x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.9B | $1.7B | $1.6B | $1.2B | $2.1B | $2.5B | $1.2B | $399M | $833M | $415M | $467M |
| Enterprise Value | $2.3B | $2.1B | $2.3B | $1.9B | $2.6B | $2.6B | $1.3B | $369M | $868M | $419M | $498M |
| P/E Ratio → | 7.36 | 6.45 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.14 | 1.95 | 3.45 | 3.47 | 7.88 | 15.78 | 69.96 | 8.17 | 40.32 | 16.46 | 17.70 |
| P/B Ratio | — | — | — | — | — | — | — | 10.43 | — | — | — |
| P/FCF | 5.71 | 5.21 | — | — | — | — | — | — | — | — | — |
| P/OCF | 5.66 | 5.17 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BCRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
BioCryst Pharmaceuticals, Inc.'s enterprise value stands at 6.6x EBITDA, 8% above its 5-year average of 6.1x. The Healthcare sector median is 14.4x, placing the stock at a 54% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.39 | 5.08 | 5.63 | 9.49 | 16.35 | 70.37 | 7.56 | 42.02 | 16.64 | 18.90 |
| EV / EBITDA | 6.59 | 6.11 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 6.62 | 6.04 | 198.14 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 6.39 | — | — | — | — | — | — | — | — | — |
BCRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
BioCryst Pharmaceuticals, Inc. earns an operating margin of 39.0%. Operating margins have expanded from -31.3% to 39.0% over the past 3 years, signaling improving operational efficiency. ROIC of 96.7% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.8% | 97.8% | 97.2% | 98.6% | 97.6% | 95.4% | 90.6% | 91.6% | 97.7% | 93.2% | 89.8% |
| Operating Margin | 39.0% | 39.0% | -0.6% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | -227.9% | -184.4% |
| Net Profit Margin | 30.2% | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.3% | -261.2% | -209.3% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | -1925.4% | -284.7% | — | — | — |
| ROA | 52.5% | 52.5% | -17.6% | -42.5% | -43.4% | -39.9% | -71.7% | -67.6% | -62.3% | -49.1% | -51.4% |
| ROIC | 96.7% | 96.7% | -0.7% | -38.8% | -179.6% | — | — | — | — | — | — |
| ROCE | 105.2% | 105.2% | -0.7% | -25.6% | -32.0% | -49.8% | -112.0% | -124.1% | -104.2% | -82.7% | -101.7% |
BCRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
BioCryst Pharmaceuticals, Inc. carries a Debt/EBITDA ratio of 1.4x, which is manageable (58% below the sector average of 3.3x). Net debt stands at $388M ($477M total debt minus $90M cash). Interest coverage of 4.4x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | 2.21 | — | — | — |
| Debt / EBITDA | 1.39 | 1.39 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — | — | -0.77 | — | — | — |
| Net Debt / EBITDA | 1.13 | 1.13 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 1.18 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 4.39 | 4.39 | 0.12 | -1.09 | -1.47 | -2.07 | -11.61 | -8.16 | -10.03 | -6.68 | -7.50 |
BCRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
BioCryst Pharmaceuticals, Inc.'s current ratio of 2.06x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 3.31x to 2.06x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.06 | 2.06 | 2.63 | 3.31 | 4.90 | 5.46 | 3.06 | 1.78 | 1.65 | 1.68 | 1.23 |
| Quick Ratio | 2.03 | 2.03 | 2.58 | 3.12 | 4.63 | 5.31 | 3.00 | 1.78 | 1.62 | 2.18 | 1.22 |
| Cash Ratio | 1.40 | 1.40 | 2.00 | 2.59 | 4.02 | 4.89 | 2.84 | 1.48 | 1.50 | 1.53 | 1.01 |
| Asset Turnover | — | 1.70 | 0.92 | 0.64 | 0.49 | 0.27 | 0.05 | 0.28 | 0.14 | 0.14 | 0.29 |
| Inventory Turnover | 3.53 | 3.53 | 1.54 | 0.16 | 0.24 | 0.46 | 0.24 | — | 0.29 | — | 5.40 |
| Days Sales Outstanding | — | 44.57 | 64.03 | 62.72 | 68.19 | 68.31 | 177.17 | 165.52 | 75.87 | 88.65 | 121.44 |
BCRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
BioCryst Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 13.6% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 13.6% | 15.5% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 17.5% | 19.2% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $219M | $207M | $192M | $186M | $179M | $167M | $116M | $103M | $84M | $74M |
Peer Comparison
Compare BCRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BCRXYou | $2B | 7.4 | 6.6 | 5.7 | 97.8% | 39.0% | — | 96.7% | 1.4 |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ARGX | $49B | 40.1 | 46.6 | 57.7 | 89.1% | 23.4% | 20.2% | 18.3% | 0.1 |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 AKRO | $4B | -14.6 | — | — | — | — | -39.2% | -55.3% | — |
 KALV | $1B | -7.2 | — | — | — | — | -121.5% | -152.3% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See BCRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCRX vs RARE
Side-by-side business, growth, and profitability comparison vs Ultragenyx Pharmaceutical Inc..
Start ComparisonBCRX — Frequently Asked Questions
Quick answers to the most common questions about buying BCRX stock.
What is BioCryst Pharmaceuticals, Inc.'s P/E ratio?
BioCryst Pharmaceuticals, Inc.'s current P/E ratio is 7.4x. The historical average is 6.4x. This places it at the 100th percentile of its historical range.
What is BioCryst Pharmaceuticals, Inc.'s EV/EBITDA?
BioCryst Pharmaceuticals, Inc.'s current EV/EBITDA is 6.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 6.1x.
Is BCRX stock overvalued?
Based on historical data, BioCryst Pharmaceuticals, Inc. is trading at a P/E of 7.4x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are BioCryst Pharmaceuticals, Inc.'s profit margins?
BioCryst Pharmaceuticals, Inc. has 97.8% gross margin and 39.0% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does BioCryst Pharmaceuticals, Inc. have?
BioCryst Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 1.4x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.